Xun Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Xun Tang has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Yonghua Hu
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
28 shared publications - Pei Gao
Institute of Advanced Clinical Medicine, Peking University
23 shared publications Na Li
Fangshan District Center for Disease Control and Prevention, Beijing, China
14 shared publications- Yiqun Wu
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
13 shared publications Hongbo Lin
Department of Chronic Diseases and Health Promotion, Yinzhou District Centre for Disease Control and Prevention, Ningbo, China
10 shared publicationsPeng Shen
Department of Chronic Diseases and Health Promotion, Yinzhou District Centre for Disease Control and Prevention, Ningbo, China
10 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (10) , e1005263
Seeing the invisible: Reorienting cardiovascular risk prediction across the disease trajectory
Current risk equations miss many cardiovascular events in people classified as low risk. Prediction is simultaneously advancing on two axes: broadening predictors toward molecular omics, and expanding outcomes toward earlier subclinical atherosclerosis and later heart failure.
- 21 October 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (10) , e1005263
Open AccessSeeing the invisible: Reorienting cardiovascular risk prediction across the disease trajectory
Current risk equations miss many cardiovascular events in people classified as low risk. Prediction is simultaneously advancing on two axes: broadening predictors toward molecular omics, and expanding outcomes toward earlier subclinical atherosclerosis and later heart failure.
- Open Access
Simultaneous derivation, validation, and comparison of predictor hazard ratios for cardiovascular risk prediction equations in patients with diabetes from high versus non-high income countries: cohort study
Objective: To directly test the generalisability of cardiovascular disease (CVD) risk predictor effects across populations in a high income versus non-high income country, derive comparable risk equations, and identify more effective strategies for prediction across populations. Design: Population based cohort study. Setting: Primary prevention cohorts in New Zealand and China. Participants: Equivalent New Zealand and Chinese cohorts of people aged 30-74 years with diabetes and no CVD based on electronic health records. Main outcome measures: Country specific five year equations were derived using standardised methods to predict first cardiovascular events; predictor hazard ratios were compared. New Zealand equations were applied to the Chinese cohort, with performance assessed before and after standard recalibration, followed by the updating of predictor hazard ratios that differed statistically significantly. Results: Between 2004 and 2018, 47 958 New Zealand participants had 5622 (11.7%) first CVD events. Between 2010 and 2018, 46 558 Chinese participants had 3650 (7.8%) first CVD events. Sex specific equations included 16 predictors. Hazard ratios for most predictors were similar between New Zealand and Chinese equations but differed markedly for age (eg, women: 1.61, 95% confidence interval 1.51 to 1.71 per 10 years in New Zealand, 2.51 (2.32 to 2.72) per 10 years in China). Standard recalibration of New Zealand equations did not improve calibration in the Chinese cohort (expected to observed ratio: 0.938 in men, 0.809 in women). Replacing New Zealand age coefficients with Chinese coefficients noticeably improved calibration (expected to observed ratio 1.027 in men, 1.025 in women). Conclusions: Applying a high income country derived CVD risk prediction equation to a population from a non-high income country with diabetes may introduce systematic errors, primarily driven by differences in the effect of age. Moving beyond simple recalibration to updating key predictor coefficients, particularly age, should be considered for more accurate risk stratification. This study highlights potential limitations of high income country equation updating practices and proposes a feasible approach to improve their accuracy when used in populations from non-high income countries.
Open AccessSimultaneous derivation, validation, and comparison of predictor hazard ratios for cardiovascular risk prediction equations in patients with diabetes from high versus non-high income countries: cohort study
Objective: To directly test the generalisability of cardiovascular disease (CVD) risk predictor effects across populations in a high income versus non-high income country, derive comparable risk equations, and identify more effective strategies for prediction across populations. Design: Population based cohort study. Setting: Primary prevention cohorts in New Zealand and China. Participants: Equivalent New Zealand and Chinese cohorts of people aged 30-74 years with diabetes and no CVD based on electronic health records. Main outcome measures: Country specific five year equations were derived using standardised methods to predict first cardiovascular events; predictor hazard ratios were compared. New Zealand equations were applied to the Chinese cohort, with performance assessed before and after standard recalibration, followed by the updating of predictor hazard ratios that differed statistically significantly. Results: Between 2004 and 2018, 47 958 New Zealand participants had 5622 (11.7%) first CVD events. Between 2010 and 2018, 46 558 Chinese participants had 3650 (7.8%) first CVD events. Sex specific equations included 16 predictors. Hazard ratios for most predictors were similar between New Zealand and Chinese equations but differed markedly for age (eg, women: 1.61, 95% confidence interval 1.51 to 1.71 per 10 years in New Zealand, 2.51 (2.32 to 2.72) per 10 years in China). Standard recalibration of New Zealand equations did not improve calibration in the Chinese cohort (expected to observed ratio: 0.938 in men, 0.809 in women). Replacing New Zealand age coefficients with Chinese coefficients noticeably improved calibration (expected to observed ratio 1.027 in men, 1.025 in women). Conclusions: Applying a high income country derived CVD risk prediction equation to a population from a non-high income country with diabetes may introduce systematic errors, primarily driven by differences in the effect of age. Moving beyond simple recalibration to updating key predictor coefficients, particularly age, should be considered for more accurate risk stratification. This study highlights potential limitations of high income country equation updating practices and proposes a feasible approach to improve their accuracy when used in populations from non-high income countries.
- Open Access
- 7 April 2026
- Published by Springer Nature in Scientific Data
- Vol. 13 (1)
Synthetic data Using Population Profiles for cardiOvascular Risk facTors (SUPPORT) in mainland China
Publicly available synthetic population datasets often lack detailed health information, limiting their utility in disease modeling. To address this gap, we present the SUPPORT (Synthetic data Using Population Profiles for cardiOvascular Risk facTors) dataset, a large-scale cross-sectional resource comprising 777,358,492 synthetic individuals aged 35–84 across seven geographic regions of China, anchored to the year 2020 demographic structure. Each synthetic individual possesses a detailed profile of sociodemographic attributes and major cardiovascular disease (CVD) risk factors, including blood pressure, cholesterol levels, body mass index, and a history of diabetes. The population was constructed using iterative proportional fitting, multivariate normal distribution sampling, and multiple imputation, integrating data from China’s Seventh National Population Census (2020), the Global Burden of Disease (GBD) study, and numerous health surveys. Technical validation against census statistics and independent cohorts, including the China Kadoorie Biobank, confirmed that the dataset accurately replicates marginal sociodemographic distributions and adequately approximates cardiovascular risk profiles of real-world populations. The open-source SUPPORT dataset can be extended with additional attributes, providing a publicly available resource to enable robust, individual-level modeling of CVD.
- 7 April 2026
- Published by Springer Nature in Scientific Data
- Vol. 13 (1)
Open AccessSynthetic data Using Population Profiles for cardiOvascular Risk facTors (SUPPORT) in mainland China
Publicly available synthetic population datasets often lack detailed health information, limiting their utility in disease modeling. To address this gap, we present the SUPPORT (Synthetic data Using Population Profiles for cardiOvascular Risk facTors) dataset, a large-scale cross-sectional resource comprising 777,358,492 synthetic individuals aged 35–84 across seven geographic regions of China, anchored to the year 2020 demographic structure. Each synthetic individual possesses a detailed profile of sociodemographic attributes and major cardiovascular disease (CVD) risk factors, including blood pressure, cholesterol levels, body mass index, and a history of diabetes. The population was constructed using iterative proportional fitting, multivariate normal distribution sampling, and multiple imputation, integrating data from China’s Seventh National Population Census (2020), the Global Burden of Disease (GBD) study, and numerous health surveys. Technical validation against census statistics and independent cohorts, including the China Kadoorie Biobank, confirmed that the dataset accurately replicates marginal sociodemographic distributions and adequately approximates cardiovascular risk profiles of real-world populations. The open-source SUPPORT dataset can be extended with additional attributes, providing a publicly available resource to enable robust, individual-level modeling of CVD.
- Open Access
- 22 July 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (7) , e1004556
Absolute risk-based versus individualized benefit approaches for determining statin eligibility in primary prevention of cardiovascular diseases in Chinese populations: A modeling study
Background: Current guidelines for statin use in primary prevention of cardiovascular disease (CVD) predominantly rely on absolute 10-year CVD risk scores. However, this approach may not adequately capture heterogeneity in the potential benefit of low-density lipoprotein cholesterol (LDL-C) reduction. This study compares the absolute risk-based approach with an individualized benefit approach, based on the Causal-Benefit model considering predicted lipid-lowering effects, for statin eligibility in Chinese populations. Methods and Findings: We analyzed nationally representative data from the China Health and Retirement Longitudinal Study, including adults aged 40–80 years, free of diabetes and CVD history, with LDL-C levels between 1.8 mmol/L and 4.9 mmol/L, and no prior statin use. Statin eligibility was determined using two strategies: (i) the absolute risk-based approach (10-year CVD risk), and (ii) the individualized benefit approach (using the Causal-Benefit model framework incorporating predicted individual absolute risk reduction [iARR]). We estimated eligible populations, CVD events averted, and number needed to treat (NNT) both at population and individual level (iNNT) over 10 years versus no treatment, assessed discordance, and primarily calibrated the benefit threshold to match event prevention by the risk-based approach for comparison. A total of 7,287 adults were analyzed, forming a cohort reflective of 324.6 million Chinese adults (mean age 57 years; 51.7% women). To prevent a similar number of CVD events (2.19 million vs. 2.16 million), 49.2 million (95% confidence interval [CI]: 45.3,53.0) and 50.3 million (95% CI: 46.0,54.6) adults would be eligible for statins therapy under the individualized benefit and absolute risk-based approaches, respectively. Among 58.9 million adults eligible for either strategy, the concordance was only 68.9%. The benefit approach alone identified 8.6 million people highly benefit from statin therapy, who would not be eligible for statin therapy under the absolute risk-based approach, and this includes 1.3 million people with borderline risk (5% to 7.5%). Conversely, the risk-based approach selected more individuals with low predicted benefit (minimum iARR: 2.5% vs. 3.4%), resulting in a less efficient individual-level targeting profile (maximum iNNT: 41 vs. 29). A key limitation of this study is that benefit was estimated primary from LDL-C reduction, which may neglect other biological mechanisms of statin effects and underestimate the total benefit. Conclusions: The individualized benefit approach prioritizes individuals most likely to benefit from statin therapy, differing from conventional risk-based selection through its superior individual-level precision. This approach can enhance the capacity to discriminate treatment effects at the individual level, making it particularly valuable for shared decision-making in resource-constrained settings.
- 22 July 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (7) , e1004556
Open AccessAbsolute risk-based versus individualized benefit approaches for determining statin eligibility in primary prevention of cardiovascular diseases in Chinese populations: A modeling study
Background: Current guidelines for statin use in primary prevention of cardiovascular disease (CVD) predominantly rely on absolute 10-year CVD risk scores. However, this approach may not adequately capture heterogeneity in the potential benefit of low-density lipoprotein cholesterol (LDL-C) reduction. This study compares the absolute risk-based approach with an individualized benefit approach, based on the Causal-Benefit model considering predicted lipid-lowering effects, for statin eligibility in Chinese populations. Methods and Findings: We analyzed nationally representative data from the China Health and Retirement Longitudinal Study, including adults aged 40–80 years, free of diabetes and CVD history, with LDL-C levels between 1.8 mmol/L and 4.9 mmol/L, and no prior statin use. Statin eligibility was determined using two strategies: (i) the absolute risk-based approach (10-year CVD risk), and (ii) the individualized benefit approach (using the Causal-Benefit model framework incorporating predicted individual absolute risk reduction [iARR]). We estimated eligible populations, CVD events averted, and number needed to treat (NNT) both at population and individual level (iNNT) over 10 years versus no treatment, assessed discordance, and primarily calibrated the benefit threshold to match event prevention by the risk-based approach for comparison. A total of 7,287 adults were analyzed, forming a cohort reflective of 324.6 million Chinese adults (mean age 57 years; 51.7% women). To prevent a similar number of CVD events (2.19 million vs. 2.16 million), 49.2 million (95% confidence interval [CI]: 45.3,53.0) and 50.3 million (95% CI: 46.0,54.6) adults would be eligible for statins therapy under the individualized benefit and absolute risk-based approaches, respectively. Among 58.9 million adults eligible for either strategy, the concordance was only 68.9%. The benefit approach alone identified 8.6 million people highly benefit from statin therapy, who would not be eligible for statin therapy under the absolute risk-based approach, and this includes 1.3 million people with borderline risk (5% to 7.5%). Conversely, the risk-based approach selected more individuals with low predicted benefit (minimum iARR: 2.5% vs. 3.4%), resulting in a less efficient individual-level targeting profile (maximum iNNT: 41 vs. 29). A key limitation of this study is that benefit was estimated primary from LDL-C reduction, which may neglect other biological mechanisms of statin effects and underestimate the total benefit. Conclusions: The individualized benefit approach prioritizes individuals most likely to benefit from statin therapy, differing from conventional risk-based selection through its superior individual-level precision. This approach can enhance the capacity to discriminate treatment effects at the individual level, making it particularly valuable for shared decision-making in resource-constrained settings.
- Open Access
- 2 July 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 185, 111895
A population-based recalibration method for updating survival neural networks models for cardiovascular risk prediction in United Kingdom and China
- 2 July 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 185, 111895
Open AccessA population-based recalibration method for updating survival neural networks models for cardiovascular risk prediction in United Kingdom and China
- Open Access
- 1 July 2025
- Published by BMJ in Open Heart
- Vol. 12 (2) , e003240
Association analysis of blood pressure with incident risks for thoracic and abdominal aortic aneurysms: an observational study of the UK Biobank cohort
Background: The specific relationship between different blood pressure measures and the risk of aortic aneurysms (AA) remains unclear. Elucidating these associations would be conducive to identifying high-risk individuals and developing more effective screening strategies, potentially reducing AA incidence. This study aimed to investigate the association between various blood pressure measures or subtypes of hypertension and the risk of AA. Methods: Using data from the UK biobank study, we performed multivariable Cox regression analysis to estimate HRs for baseline systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP) with risk of AA. The associations of isolated systolic hypertension, isolated diastolic and combined systolic-diastolic hypertension for AA were also assessed. Results: Our analysis included 397 019 participants without antihypertensive medication at baseline (mean age, 55.4 (SD 8.1) years; 56.6% female). We identified 1782 cases of AA during a median follow-up period of 12 years. The association between SBP and AA was weak (per-SD HR=1.03, 95% CI 0.98 to 1.08). The association between DBP and AA (per-SD HR=1.24, 95% CI 1.15 to 1.33) was significant when DBP reached 80 mm Hg and higher. Lower PP was linearly associated with increasing AA risk (per-SD HR=0.76, 95% CI 0.69 to 0.83). These patterns were consistent when comparing abdominal AA with overall cases. Compared with the normal group, the HRs of isolated systolic hypertension, isolated diastolic hypertension and combined hypertension on AA were 1.01 (95% CI 0.89 to 1.13), 1.67 (95% CI 1.27 to 2.18) and 1.35 (95% CI 1.20 to 1.52), respectively. Conclusions: Elevated DBP and reduced PP, but not SBP, were independently associated with a higher risk of incident AA, highlighting their potential to refine clinical risk stratification.
- 1 July 2025
- Published by BMJ in Open Heart
- Vol. 12 (2) , e003240
Open AccessAssociation analysis of blood pressure with incident risks for thoracic and abdominal aortic aneurysms: an observational study of the UK Biobank cohort
Background: The specific relationship between different blood pressure measures and the risk of aortic aneurysms (AA) remains unclear. Elucidating these associations would be conducive to identifying high-risk individuals and developing more effective screening strategies, potentially reducing AA incidence. This study aimed to investigate the association between various blood pressure measures or subtypes of hypertension and the risk of AA. Methods: Using data from the UK biobank study, we performed multivariable Cox regression analysis to estimate HRs for baseline systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP) with risk of AA. The associations of isolated systolic hypertension, isolated diastolic and combined systolic-diastolic hypertension for AA were also assessed. Results: Our analysis included 397 019 participants without antihypertensive medication at baseline (mean age, 55.4 (SD 8.1) years; 56.6% female). We identified 1782 cases of AA during a median follow-up period of 12 years. The association between SBP and AA was weak (per-SD HR=1.03, 95% CI 0.98 to 1.08). The association between DBP and AA (per-SD HR=1.24, 95% CI 1.15 to 1.33) was significant when DBP reached 80 mm Hg and higher. Lower PP was linearly associated with increasing AA risk (per-SD HR=0.76, 95% CI 0.69 to 0.83). These patterns were consistent when comparing abdominal AA with overall cases. Compared with the normal group, the HRs of isolated systolic hypertension, isolated diastolic hypertension and combined hypertension on AA were 1.01 (95% CI 0.89 to 1.13), 1.67 (95% CI 1.27 to 2.18) and 1.35 (95% CI 1.20 to 1.52), respectively. Conclusions: Elevated DBP and reduced PP, but not SBP, were independently associated with a higher risk of incident AA, highlighting their potential to refine clinical risk stratification.
- 18 June 2025
- Vol. 57 (3) , 430-435
[Association of triglyceride-glucose index and cardiovascular disease in a community-based Chinese cohort].
To investigate the association between the triglyceride-glucose (TyG) index and the incidence and mortality of cardiovascular disease (CVD) in a large population-based cohort. Participants aged 40-79 years without a history of CVD at baseline were drawn from the CHinese Electronic health Records Research in Yinzhou (CHERRY) study between January 1, 2010, and May 31, 2020. The TyG index was calculated using baseline triglyceride and fasting blood glucose. Cox proportional hazards models were used to assess the association between the TyG index and the composite outcome of CVD (incidence and mortality), adjusting for age, gender, education, region, smoking status, body mass index, systolic blood pressure, and total cholesterol. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Nonlinear associations between the TyG index and CVD were further evaluated using restricted cubic splines, and subgroup analyses by gender and age were conducted to explore potential differences. A total of 226 406 individuals were included, with a mean age of (55.0±9.7) years at baseline, 46.8% of whom were men, and a median TyG index of 8.68. Over a median follow-up of 7.99 years, 9 815 (4.34%) participants experienced CVD incidence or mortality. After adjusting for age, gender, education, region, smoking status, body mass index, systolic blood pressure and total cholesterol, the risk of CVD increased with higher TyG index levels (P < 0.001). The risk in the highest TyG quartile (TyG>9.10) was 42% higher than in the lowest quartile (TyG≤8.32) (HR=1.42, 95%CI: 1.34-1.51). Individuals under 60 years had a higher HR for CVD compared with those aged 60 years and above (HR: 1.71 vs. 1.27, P < 0.05). Restricted cubic spline analysis revealed a reverse L-shaped association between the TyG index and CVD risk in the overall population (P < 0.001 for nonlinear trend), with risk increasing after the TyG index exceeded 8.67. However, the threshold varied by gender, with a lower threshold in women (8.51) than in men (8.67). A significant nonlinear relationship was revealed between the TyG index and CVD risk, with a threshold effect. The risk of CVD increased once the TyG index surpassed a certain threshold, with a lower threshold in women than in men. These findings suggest that cardiovascular risk prediction and interventions based on the TyG index should be gender-stratified, and early intervention for individuals under 60 years old might have important public health implications.
- 18 June 2025
- Vol. 57 (3) , 430-435
[Association of triglyceride-glucose index and cardiovascular disease in a community-based Chinese cohort].
To investigate the association between the triglyceride-glucose (TyG) index and the incidence and mortality of cardiovascular disease (CVD) in a large population-based cohort. Participants aged 40-79 years without a history of CVD at baseline were drawn from the CHinese Electronic health Records Research in Yinzhou (CHERRY) study between January 1, 2010, and May 31, 2020. The TyG index was calculated using baseline triglyceride and fasting blood glucose. Cox proportional hazards models were used to assess the association between the TyG index and the composite outcome of CVD (incidence and mortality), adjusting for age, gender, education, region, smoking status, body mass index, systolic blood pressure, and total cholesterol. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Nonlinear associations between the TyG index and CVD were further evaluated using restricted cubic splines, and subgroup analyses by gender and age were conducted to explore potential differences. A total of 226 406 individuals were included, with a mean age of (55.0±9.7) years at baseline, 46.8% of whom were men, and a median TyG index of 8.68. Over a median follow-up of 7.99 years, 9 815 (4.34%) participants experienced CVD incidence or mortality. After adjusting for age, gender, education, region, smoking status, body mass index, systolic blood pressure and total cholesterol, the risk of CVD increased with higher TyG index levels (P < 0.001). The risk in the highest TyG quartile (TyG>9.10) was 42% higher than in the lowest quartile (TyG≤8.32) (HR=1.42, 95%CI: 1.34-1.51). Individuals under 60 years had a higher HR for CVD compared with those aged 60 years and above (HR: 1.71 vs. 1.27, P < 0.05). Restricted cubic spline analysis revealed a reverse L-shaped association between the TyG index and CVD risk in the overall population (P < 0.001 for nonlinear trend), with risk increasing after the TyG index exceeded 8.67. However, the threshold varied by gender, with a lower threshold in women (8.51) than in men (8.67). A significant nonlinear relationship was revealed between the TyG index and CVD risk, with a threshold effect. The risk of CVD increased once the TyG index surpassed a certain threshold, with a lower threshold in women than in men. These findings suggest that cardiovascular risk prediction and interventions based on the TyG index should be gender-stratified, and early intervention for individuals under 60 years old might have important public health implications.
- Open Access
- 6 May 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 250, 70-78
Incidence and Risk of Heart Failure in Patients With Coronary Heart Disease and Stroke: A Population-Based Cohort Study
- 6 May 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 250, 70-78
Open AccessIncidence and Risk of Heart Failure in Patients With Coronary Heart Disease and Stroke: A Population-Based Cohort Study
- 17 April 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
External validation of SCORE2-Diabetes risk prediction model in Chinese patients with diabetes
Aims: The updated 2023 European Guideline recommended SCORE2-Diabetes to estimate cardiovascular disease (CVD) risk in patients with diabetes; however, external validation is lacking. The study aims to validate SCORE2-Diabetes in Chinese and assess its broader applicability and adaptability across diverse settings. Methods and results: This study included patients with diabetes aged 40–90 without prior CVD from a population-based Chinese cohort. Ten-year CVD risk was calculated using the original and recalibrated SCORE2-Diabetes, where four sets of scaling factors for different risk regions were provided. The outcome was defined consistently with SCORE2-Diabetes. During a median follow-up of 7.09 years, 50 426 Chinese patients experienced 6540 CVD events and 2852 non-CVD deaths. The C-statistic of the SCORE2-Diabetes was 0.702 (95% confidence interval: 0.691–0.713) in men and 0.726 (0.716–0.736) in women. The original SCORE2-Diabetes underestimated risk by 30% in men and 50% in women, whereas the recalibrated SCORE2-Diabetes using high-risk region scaling factor had the best calibration, overestimating risk by only 4% in men and underestimating by 7% in women. Of the patients, 14 501 (28.76%) and 20 789(41.23%) were classified as very high (≥20%) and high (10–20%) risk categories, respectively. The significant difference between average baseline and targeted LDL-C was observed in the very high-risk group (2.85 vs. 1.40 mmol/L). Conclusion: With the appropriate selection of the scaling factor, SCORE2-Diabetes shows satisfactory discrimination and calibration in Chinese, indicating its good generalizability. According to the latest guideline, the risk assessment in this real-world population indicated a significant demand for medications with cardiovascular efficacy and a substantial burden for lipid management.
- 17 April 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
External validation of SCORE2-Diabetes risk prediction model in Chinese patients with diabetes
Aims: The updated 2023 European Guideline recommended SCORE2-Diabetes to estimate cardiovascular disease (CVD) risk in patients with diabetes; however, external validation is lacking. The study aims to validate SCORE2-Diabetes in Chinese and assess its broader applicability and adaptability across diverse settings. Methods and results: This study included patients with diabetes aged 40–90 without prior CVD from a population-based Chinese cohort. Ten-year CVD risk was calculated using the original and recalibrated SCORE2-Diabetes, where four sets of scaling factors for different risk regions were provided. The outcome was defined consistently with SCORE2-Diabetes. During a median follow-up of 7.09 years, 50 426 Chinese patients experienced 6540 CVD events and 2852 non-CVD deaths. The C-statistic of the SCORE2-Diabetes was 0.702 (95% confidence interval: 0.691–0.713) in men and 0.726 (0.716–0.736) in women. The original SCORE2-Diabetes underestimated risk by 30% in men and 50% in women, whereas the recalibrated SCORE2-Diabetes using high-risk region scaling factor had the best calibration, overestimating risk by only 4% in men and underestimating by 7% in women. Of the patients, 14 501 (28.76%) and 20 789(41.23%) were classified as very high (≥20%) and high (10–20%) risk categories, respectively. The significant difference between average baseline and targeted LDL-C was observed in the very high-risk group (2.85 vs. 1.40 mmol/L). Conclusion: With the appropriate selection of the scaling factor, SCORE2-Diabetes shows satisfactory discrimination and calibration in Chinese, indicating its good generalizability. According to the latest guideline, the risk assessment in this real-world population indicated a significant demand for medications with cardiovascular efficacy and a substantial burden for lipid management.
- 24 March 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (5) , 897-906
Incidence of the Stevens‐Johnson syndrome spectrum and its patterns in urban China
Stevens‐Johnson syndrome (SJS) spectrum is a series of rare, but life‐threatening mucocutaneous hypersensitivity reactions. However, the epidemiological evidence of it is limited, especially in developing countries. The shape associations with age and its seasonal pattern are still uncertain. Therefore, this study aimed to describe the nationwide incidence of SJS spectrum, its associations with age and season, and its subsequent diagnosed diseases across urban China. By using national health insurance datasets from 2013 to 2017, this retrospective cohort study estimated the incidence of SJS spectrum and its associations in 23 Chinese provinces. SJS spectrum was defined to include SJS and/or toxic epidermal necrolysis (ICD‐10 code: L51.1–2). First, age‐specific incidence rates were estimated in each province and then pooled using a random‐effects model. Relative risks (RR) of SJS spectrum in different seasons were estimated by Poisson regression. Diseases diagnosed within 6 months following SJS occurrence were described. In total, 9308 patients were identified (50.17% women, median age 45). The average standardized incidence rate of SJS spectrum was 3.43 (95% confidence interval [CI] 3.04–3.84) per million person‐years, which increased by 0.57 (95% CI 0.29–0.84) per million person‐years. Incidence rates were significantly higher among children age p = 0.0036) and adults age ≥ 40 (5.50, 95% CI 4.35–6.78, p = 0.00085) than the group aged 10–40 years (3.12, 95% CI 2.29–4.07). The risk of SJS spectrum was highest in summer (vs autumn: RR = 1.83, 95% CI 1.72–1.93). The most frequently diagnosed disease within 6 months after the onset of SJS was respiratory disease (43.8%). In conclusion, this study provides evidence on the epidemiology of SJS spectrum in developing countries and supports the two‐peak distribution of its incidence across age. Its high occurrence in summer needs further confirmation.
- 24 March 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (5) , 897-906
Incidence of the Stevens‐Johnson syndrome spectrum and its patterns in urban China
Stevens‐Johnson syndrome (SJS) spectrum is a series of rare, but life‐threatening mucocutaneous hypersensitivity reactions. However, the epidemiological evidence of it is limited, especially in developing countries. The shape associations with age and its seasonal pattern are still uncertain. Therefore, this study aimed to describe the nationwide incidence of SJS spectrum, its associations with age and season, and its subsequent diagnosed diseases across urban China. By using national health insurance datasets from 2013 to 2017, this retrospective cohort study estimated the incidence of SJS spectrum and its associations in 23 Chinese provinces. SJS spectrum was defined to include SJS and/or toxic epidermal necrolysis (ICD‐10 code: L51.1–2). First, age‐specific incidence rates were estimated in each province and then pooled using a random‐effects model. Relative risks (RR) of SJS spectrum in different seasons were estimated by Poisson regression. Diseases diagnosed within 6 months following SJS occurrence were described. In total, 9308 patients were identified (50.17% women, median age 45). The average standardized incidence rate of SJS spectrum was 3.43 (95% confidence interval [CI] 3.04–3.84) per million person‐years, which increased by 0.57 (95% CI 0.29–0.84) per million person‐years. Incidence rates were significantly higher among children age p = 0.0036) and adults age ≥ 40 (5.50, 95% CI 4.35–6.78, p = 0.00085) than the group aged 10–40 years (3.12, 95% CI 2.29–4.07). The risk of SJS spectrum was highest in summer (vs autumn: RR = 1.83, 95% CI 1.72–1.93). The most frequently diagnosed disease within 6 months after the onset of SJS was respiratory disease (43.8%). In conclusion, this study provides evidence on the epidemiology of SJS spectrum in developing countries and supports the two‐peak distribution of its incidence across age. Its high occurrence in summer needs further confirmation.